Jans Fromow-Guerra, MD, PhD (Mexico City, Mexico), Elizabeth Reyna-Castelán, MD (Mexico City, Mexico), Juan Manuel Jimenez- Sierra, MD (Mexico City, Mexico), Adriana Solis-Vivanco, MD (Mexico City, Mexico), Jose Luis Guerrero-Naranjo, MD (Mexico City, Mexico), Maura Abraham-Marin, MD (Mexico City, Mexico), Myriam Lucia Hernández-Rojas, MD (Mexico City, Mexico), Griselda Alvarez-Rivera, MD (Mexico City, Mexico), Maria Ana Martinez- Castellanos, MD (Mexico City, Mexico), Hugo Quiroz-Mercado, MD (Mexico City, Mexico)

PURPOSE:

To evaluate the 1-month efficacy of a single dose of intravitreal (IV) bevacizumab on the progression SNPDR, PDR and APPDR by evaluation of ischemic areas and regression of retinal and disc neovascularization.

METHODS:

40 patients were enrolled in a prospective, interventional study. Patients were treated with IV bevacizumab 0.1ml (0.25mg). We evaluated visual acuity (VA), neovascularization leakage points, capillary closure ischemic areas (CCIA) and macular edema by clinical examination and fluorescein angiography. A clinical examination was performed at baseline and days 1,
14 and 30. Active leakage points were measured by fluorescein angiography at 30 days.

RESULTS:

40 patients, 65% females (n=26), 19 SNPDR (47.5%), 10 PDR (25%) and 11 (27.5%) APPDR. Mean initial visual acuity improved from 20/80 to 20/50 at one week evaluation and remain stable at 1 month (Repeated measures GLM p= 0.062).  CCIA measured in quadrants diminished significantly from 3.33±1.01 to 1.87±0.915 at 1st month (Wilcoxon ranked signed
test). Retinal and disc neovascularization leakage points and macular edema also showed significant reduction. Macular edema  disc areas diminished from 4.28±3.2 to 2.68±2 (Wilcoxon ranked signed test p< 0.0001). Ocular or systemic effects were not observed.

CONCLUSION:

These results indicates the trend that IV bevacizumab decrease ischemic areas, disc and retinal neovascularization in a 1-month follow-up. The results suggest that bevacizumab is a potent antiangiogenic that may reduce the progression of PPDR, PDR and APPDR in a 1-month follow-up.